Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 19Xls
2D Structure
Also known as: 10034-93-2, Hydrazine, sulfate, Hydrazine monosulfate, Hydrazine sulphate, Hydrazinium sulfate, Hydrazonium sulfate
Molecular Formula
H6N2O4S
Molecular Weight
130.13  g/mol
InChI Key
ZGCHATBSUIJLRL-UHFFFAOYSA-N
FDA UNII
1N369SAT01

Hydrazine Sulfate is the synthetic sulfate salt of hydrazine, a derivative of ammonia. Hydrazine inhibits the enzyme phosphoenol pyruvate carboxykinase, thereby blocking gluconeogenesis. This agent has been reported to decrease the excessive energy needs and cachexia of cancer patients. Classified as a likely human carcinogen, hydrazine sulfate is also a weak inhibitor of mono-amine oxidase (MAO). (NCI04)
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
hydrazine;sulfuric acid
2.1.2 InChI
InChI=1S/H4N2.H2O4S/c1-2;1-5(2,3)4/h1-2H2;(H2,1,2,3,4)
2.1.3 InChI Key
ZGCHATBSUIJLRL-UHFFFAOYSA-N
2.1.4 Canonical SMILES
NN.OS(=O)(=O)O
2.2 Other Identifiers
2.2.1 UNII
1N369SAT01
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Hydrazine

2. Hydrazine Dihydrochloride

3. Hydrazine Hydrate

4. Hydrazine Monohydrate

5. Hydrazine Mononitrate

6. Hydrazine Nitrate

7. Hydrazine Phosphate (1:1)

8. Hydrazine Phosphate (2:1)

9. Hydrazine Sulfate (1:1) Monosodium Salt

10. Hydrazine Sulfate (2:1)

11. Hydrazine Tartrate

12. Segidrin

2.3.2 Depositor-Supplied Synonyms

1. 10034-93-2

2. Hydrazine, Sulfate

3. Hydrazine Monosulfate

4. Hydrazine Sulphate

5. Hydrazinium Sulfate

6. Hydrazonium Sulfate

7. Hydrazine Sulfate (1:1)

8. Hydrazine, Sulfate (1:1)

9. Siran Hydrazinu

10. Idrazina Solfato

11. Hydrazinium(2+) Sulfate

12. Hydrazine Hydrogen Sulfate

13. Hydrazine Sulfate Salt

14. Nsc-150014

15. Hydrazine Dihydrogen Sulfate Salt

16. Mfcd00044873

17. 1n369sat01

18. Nsc150014

19. Nsc-215190

20. Segidrin

21. Sehydrin

22. Diamidogen Sulfate

23. Hydrazinium(2+) Sulphate

24. Wln: Zz &s-o4

25. Siran Hydrazinu [czech]

26. Hydrazine Sulfate (van)

27. Idrazina Solfato [italian]

28. Hydrazinium Sulphate

29. Ccris 336

30. Hsdb 5086

31. Hydrazine; Sulfuric Acid

32. Einecs 233-110-4

33. Nsc 150014

34. Nsc 215190

35. Hydrazinsulfat

36. Idrazina Solfato [italian]

37. Unii-1n369sat01

38. Ai3-18433

39. Hydrazine Sulphate Salt

40. Dsstox_cid_703

41. Hydrazonium Sulphate

42. Hydrazine Dihydrogen Sulfate

43. Dsstox_rid_75745

44. Hydrazine Monosulphate

45. Dsstox_gsid_20703

46. Hydrazine Sulfate [mi]

47. Chembl1981828

48. Dtxsid8020703

49. Hydrazine Sulfate [hsdb]

50. Amy8941

51. Hydrazine Hydrogen Sulphate

52. Hydrazine Sulfate [mart.]

53. Hydrazine Sulfate [who-dd]

54. Hydrazine, Sulphate (1:1)

55. Tox21_302995

56. Gp-703

57. Nsc215190

58. Akos015901874

59. Hydrazinium Sulfate, Hydrazonium Sulfate

60. Ncgc00256445-01

61. Nci60_001038

62. Cas-10034-93-2

63. Db-029899

64. Hydrazine Dihydrogen Sulfate (1:1)

65. Ft-0627114

66. Hydrazine Dihydrogen Sulphate (1:1)

67. Hydrazine Sulfate Salt, Acs Reagent, >=99.0%

68. Hydrazinium Sulfate, Saj First Grade, >=97.0%

69. Hydrazinium Sulfate, Jis Special Grade, >=99.0%

70. Q413847

71. Hydrazine Sulfate Salt, P.a., Acs Reagent, 99.0%

72. Hydrazine Sulfate Salt, 99.999% Trace Metals Basis

73. Hydrazine Sulfate Salt, Vetec(tm) Reagent Grade, 97%

74. Hydrazine Sulfate Salt, Puriss. P.a., Acs Reagent, >=99.0%

2.4 Create Date
2005-03-26
3 Chemical and Physical Properties
Molecular Weight 130.13 g/mol
Molecular Formula H6N2O4S
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count6
Rotatable Bond Count0
Exact Mass130.00482785 g/mol
Monoisotopic Mass130.00482785 g/mol
Topological Polar Surface Area135 Ų
Heavy Atom Count7
Formal Charge0
Complexity81.3
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Therapeutic Uses

Antineoplastic Agents /Former use/

National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)


In the 1980's and early 1990's the National Cancer Institute (NCI) sponsored studies of hydrazine sulfate to evaluate whether the compound might improve patient survival or help reverse cancercachexia, a wasting syndrome that occurs in many patients who have advanced cancer. ... After hydrazine sulfate showed promising results in a small pilot study three large scale , randomized clinical trials of the compound were conducted with patients with advanced cancers. ... In two of the three clinical trials patients were permitted to take tranquilizers, alcohol, and barbiturates. ... At the request of Congress, the General Accounting Office (GAO) examined this issue beginning in July 1994 and ending in April 1995. The GAO concluded that although tranquilizers, alcohol, and barbiturates were permitted, the use of these substances did not affect the findings of these studies

DHHS;NCI Studies of Hydrazine Sulfate, Cancer Facts 9.18 (February 2001). Available from, as of July 28, 2004: https://cis.nci.nih.gov/fact/9_18.htm


Hydrazine sulfate was evaluated using 24 hour dietary recalls and body weight determinations before and after 30 days of either placebo or hydrazine (60 mg, 3 times a day) oral administration in 101 heavily pretreated cancer patients with weight loss /from cancer cachexia/. After one month, 83% of hydrazine and only 53% of placebo patients completing repeat evaluation maintained or increased their weight (P< 0.05). In addition, appetite was more frequent in the hydrazine group (63% versus 25%, P< 0.05).

PMID:3791153 Chlebowski RT et al; Cancer 59 (3): 406-10 (1987)


The growth of exptl tumors involved an intensification of acetylation of sulfadimidine. Inhibition of carcinosarcoma Walker-256 by 88% and sarcoma-180 by 36% on treatment of rats & mice with 60 mg/kg of hydrazine sulfate was followed by decreases in rate of acetylation of 39.4 & 29.4%, respectively. When treatment failed to suppress tumor growth (sarcoma-45), acetylation level showed no decrease. The results point to a correlation between growth of tumors & their inhibition on the one hand & the level of acetylation on the other.

PMID:1026855 Dilman et al; Oncology 33 (5-6): 219-21 (1976)


For more Therapeutic Uses (Complete) data for HYDRAZINE SULFATE (7 total), please visit the HSDB record page.


4.2 Drug Warning

A 55-year-old man with squamous-cell carcinoma of the left maxillary sinus presented with a 2-week history of rash, pruritus, progressive malaise, and jaundice. The patient had previously declined to undergo surgery, radiation, and chemotherapy. To treat his cancer, the patient had instead decided to use hydrazine sulfate he obtained through an alternative medicine Internet site. ...Two weeks before his presentation, he had discontinued /4 months/ use of hydrazine sulfate, 180 mg/d ... No esophageal or gastric varices were detected. The patient never recovered from this episode despite aggressive treatment.

PMID:11103057 Hainer M et al; Annals of Internal Medicine 133(11): 877-880 (2000)


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


Carcinogens

Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)


5.2 Absorption, Distribution and Excretion

/Following/ a single ip administration to mice, 1 mmol/kg hydrazine sulfate was distributed rapidly to most tissues with highest levels appearing in kidney. Loss from all tissues was extensive by 24 hr. Within 1st 1 to 2 hr after administration of (15)N-hydrazine sulfate, approx 20% of dose was expired as (15)N and by 48 hr another 10-15% was eliminated.

NELSON SD, GORDON WP; ADV EXP MED BIOL 136B (BIOL REACT INTERMED-2, CHEM MECH BIOL EFF PART B) 971 (1982)


5.3 Metabolism/Metabolites

When hydrazine sulfate (1 mmole/kg) was injected ip in the rat, approx 15% was converted to nitrogen within the first 30 min, followed by a much slower conversion during 24 hr. The highest conversion was observed with iv doses, and lowest with sc doses.

DOST FN; AEROSP MED RES LAB, (TECH REP) AMRL-TR (US); ISS AMRL-TR-79-68 PROC CONF ENVIRON TOXICOL 87-100 (1979)


The enzyme systems in rat liver and lung responsible for the oxidative metabolism of hydrazine derivatives were studied to determine whether these enzymes, cytochrome p450 and monoamine oxidase, were responsible for metabolically activating hydrazines to carcinogenic/toxic metabolites. Cytochrome p450 preferentially oxidized the nitrogen to nitrogen bond of 1,2-disubstituted hydrazines and hydrazides, while monoamine oxidase oxidized the nitrogen to nitrogen bond of all the classes of hydrazine derivatives that were tested. Oxidation of the nitrogen to nitrogen bond led to the formation of stable azo intermediates in the case of 1,2-disubstituted hydrazines and to unstable monoazo (diazene) metabolites in the case of monosubstituted hydrazines and hydrazides. /Substituted hydrazines/

PMID:3271870 Erikson JM, Prough RA; J Biochem Toxicol 1 (1): 41-52 (1986)


5.4 Mechanism of Action

The chemical carcinogen hydrazine is potent stimulator of guanylate cyclase. 1,1-Dimethylhydrazine and hydrazine sulfate, two chemical carcinogens, structurally related to hydrazine decrease guanylate cyclase activity in rat tissues. Hydrazine increased DNA synthesis, but 1,1-dimethylhydrazine & hydrazine sulfate decreased DNA synthesis. The relationship, if any, linking the guanylate cyclase cyclic GMP system to DNA synthesis & carcinogenesis remains to be explored.

Vesely DL et al; Enzyme 23 (5): 289-94 (1979)